Toxicology – Cantharidin (Blister Beetle)

Core concept

Cantharidin is a potent vesicant toxin produced by blister beetles of the family Meloidae.

The classic systemic poisoning syndrome is:

Severe mucosal irritation/GI bleeding → urinary tract injury + hematuria → acute kidney injury ± multiorgan toxicity

Important severe manifestations include:

• Hematemesis
• Hematuria
• Acute kidney injury
• Coagulopathy
• Seizures
• Shock
• Cardiac dysrhythmias

There is no specific antidote.

Current FDA labeling specifically warns that oral cantharidin exposure can cause life-threatening or fatal toxicity, including severe GI injury, renal failure, coagulopathy, seizures, and flaccid paralysis.

Sources

Blister Beetles

Cantharidin is produced by multiple species of Meloidae, including historically important species such as:

• Lytta vesicatoria — “Spanish fly”
• Epicauta species
• Mylabris species

Cantharidin may constitute approximately 0.2–5% of beetle dry weight, depending on species and other factors.

“Spanish Fly”

Cantharidin-containing preparations have historically been sold as:

• Aphrodisiacs
• Abortifacients
• Traditional remedies

The so-called aphrodisiac effect results from irritation and inflammation of the urinary/genital tract, not enhancement of normal sexual physiology.

Genitourinary irritation may cause:

Pelvic vascular congestion → painful erection/priapism

This is a toxic effect.

Current Therapeutic Use

The older statement that cantharidin is available only as a 1% wart treatment is outdated.

In the United States, FDA approved YCANTH® in 2023:

Cantharidin topical solution 0.7%

for:

Molluscum contagiosum in adults and children ≥2 years

It is administered by trained healthcare professionals.

Each mL contains:

7 mg cantharidin

and each single-use applicator contains approximately:

0.45 mL

or roughly 3.15 mg cantharidin.

Cantharidin is also used in compounded dermatologic preparations for selected lesions such as warts, but these should not be confused with the current FDA-approved indication.

Toxic Dose

The human dose-response relationship is imprecise.

Published reviews estimate that potentially fatal oral exposure may occur around:

10–60 mg of pure cantharidin

although substantial variation exists between cases.

Historical fatal cases have involved estimated doses of approximately:

26–45 mg

of cantharidin.

Therefore:

Very small quantities of concentrated cantharidin can cause severe or fatal poisoning.

Do not rely on a fixed milligram threshold to determine safety because:

• Concentration may be uncertain
• Traditional preparations are poorly standardized
• Beetle toxin content varies
• Patient susceptibility varies

Pathophysiology

Cantharidin is:

• Lipophilic
• A powerful vesicant
• A strong mucosal irritant

A major molecular mechanism is inhibition of:

Protein phosphatase 1 (PP1)

and

Protein phosphatase 2A (PP2A).

This disrupts cellular phosphorylation signaling and contributes to:

• Cellular injury
• Loss of epithelial adhesion
• Inflammation
• Apoptosis
• Tissue necrosis

Vesicant Effect

Cantharidin causes:

Epithelial injury → acantholysis → vesicle/bulla formation

This accounts for its therapeutic blister-forming action on skin and its dangerous effects after inappropriate exposure.

When ingested:

Mouth/esophagus/stomach → erosions, blistering, hemorrhage

When excreted through the urinary tract:

Kidneys/ureters/bladder/urethra → irritation, hemorrhage, hematuria

Renal Toxicity

Cantharidin is strongly associated with kidney injury.

Pathologic effects described include:

• Glomerular injury
• Tubular epithelial degeneration
• Tubular obstruction
• Hemorrhage involving the renal pelvis and urinary tract

Systemic poisoning may progress:

Hematuria/proteinuria → oliguria → acute kidney injury → renal failure

Clinical Features

Onset

Symptoms commonly begin approximately:

2–4 hours after ingestion

although reported onset ranges from minutes to many hours.

Severe multiorgan injury may become increasingly evident during the subsequent 24–48 hours.

HEENT / Mucosal Injury

Early findings may include:

• Burning mouth
• Burning throat
• Oral erythema
• Vesicles
• Bullae
• Ulceration
• Dysphagia
• Painful swallowing
• Oral bleeding

The severity generally increases with toxin concentration.

Current FDA labeling warns that cantharidin must not be used orally, on mucosa, or around the eyes.

Gastrointestinal

GI toxicity is one of the most characteristic manifestations.

Possible findings include:

• Severe epigastric burning
• Crampy abdominal pain
• Nausea
• Vomiting
• Hematemesis
• Diarrhea
• Hematochezia
• Occult GI bleeding

Severe mucosal damage may resemble corrosive gastrointestinal injury.

Genitourinary

Characteristic findings include:

• Dysuria
• Urinary frequency
• Flank/lumbar pain
• Hematuria
• Proteinuria

Hematuria may be:

• Microscopic
• Gross

and can persist after other symptoms begin to improve.

Priapism

Cantharidin may cause:

• Genital edema
• Genital blistering
• Painful urinary symptoms
• Priapism

The historic reputation as “Spanish fly” derives partly from this pathologic genital vascular congestion.

Renal

Renal manifestations include:

• Hematuria
• Proteinuria
• Granular urinary casts
• Oliguria
• Rising creatinine
• Acute kidney injury

Severe renal failure is one of the principal causes of death in reported systemic poisonings.

Possible secondary electrolyte abnormalities include:

• Hyperkalemia
• Hyponatremia
• Hypocalcemia

Cardiovascular

Possible findings include:

• Sinus tachycardia
• Nonspecific ECG abnormalities
• Hypotension

Severe poisoning can progress to:

• Shock
• Ventricular dysrhythmias
• Ventricular fibrillation
• Circulatory failure

Recent reviews identify acute circulatory failure together with acute renal failure among important causes of death.

Hematologic

Severe poisoning may produce:

• Gastrointestinal hemorrhage
• Urinary bleeding
• Thrombocytopenia
• Coagulation abnormalities
• Disseminated intravascular coagulation

Current FDA labeling specifically lists coagulopathy among serious consequences of oral ingestion.

Hepatic

Systemic poisoning can cause:

• Elevated aminotransferases
• Hepatocellular injury
• Hepatic necrosis in severe cases

Recent mechanistic literature suggests cantharidin can induce:

• Oxidative stress
• Apoptosis
• Autophagic dysfunction
• Endoplasmic-reticulum stress

in hepatic tissue.

Neurologic

Severe toxicity may cause:

• Confusion
• Lethargy
• Altered consciousness
• Seizures
• Coma
• Flaccid paralysis

CNS abnormalities should also prompt evaluation for:

• Shock
• Electrolyte disturbance
• Renal failure
• Hypoxia

Pulmonary

The lungs are not usually the primary target.

Severe systemic poisoning has nevertheless been associated with:

• Pulmonary hemorrhage
• Pulmonary edema
• Respiratory distress
• Aspiration pneumonia

Dermatologic Exposure

Cantharidin is intentionally a vesicant.

Local exposure may cause:

• Erythema
• Pain
• Pruritus
• Vesicles
• Bullae
• Erosion
• Ulceration

In current controlled trials of 0.7% topical cantharidin, local skin reactions occurred in 97% of treated patients, although these were predominantly expected treatment-site reactions.

Accidental exposure to normal skin should be removed promptly.

Ocular Exposure

This is potentially very serious.

Current FDA labeling reports possible:

• Severe ocular injury
• Corneal necrosis
• Deep ocular injury
• Ocular perforation

after eye exposure.

Therefore:

Immediately irrigate eyes with water for at least 15 minutes and obtain urgent medical/ophthalmologic assessment.

Diagnosis

Diagnosis is primarily clinical:

Exposure to blister beetle/cantharidin preparation + GI mucosal injury + hematuria/renal abnormalities

There is no routinely available rapid bedside cantharidin assay.

Specialized analytical techniques such as:

• GC-MS
• LC-MS/MS

may confirm exposure in forensic or specialized settings but do not guide immediate resuscitation.

Essential Investigations

For symptomatic ingestion obtain:

Hematologic

• CBC
• Hemoglobin/hematocrit
• Platelet count

Renal

• Electrolytes
• BUN
• Creatinine
• Urinalysis
• Urine output

Hepatic

• AST
• ALT
• Bilirubin

Acid–base

For severe disease:

• Blood gas
• Lactate

Coagulation Studies

In moderate or severe poisoning obtain:

• PT/INR
• aPTT
• Fibrinogen
• D-dimer when DIC is suspected

Cardiac Monitoring

Obtain:

• 12-lead ECG
• Continuous cardiac monitoring

in significant systemic poisoning because serious ventricular dysrhythmias have been reported.

Gastrointestinal Evaluation

Significant:

• Hematemesis
• Persistent dysphagia
• Severe chest/epigastric pain
• Major GI hemorrhage

may warrant gastroenterology consultation.

Endoscopic evaluation should be individualized because the mucosa may be severely friable or injured.

Differential Diagnosis

Consider other causes of:

GI irritation/bleeding + renal injury

including:

• Arsenic
• Mercuric chloride
• Colchicine
• Podophyllin
• Caustic ingestion
• Severe gastroenteritis
• Other nephrotoxic natural products

For hematuria consider:

• Glomerulonephritis
• Nephrolithiasis
• Hemorrhagic cystitis
• Coagulopathy
• Other nephrotoxins

Treatment

1. Initial Stabilization

Management begins with:

• Airway assessment
• Breathing/oxygenation
• IV access
• Hemodynamic assessment
• Continuous monitoring in significant toxicity

Treatment is primarily:

Supportive care

because there is no proven antidote.

2. Fluid Resuscitation

Patients may lose substantial fluid through:

• Vomiting
• GI bleeding
• Reduced oral intake

Use isotonic crystalloid to correct clinically significant volume depletion.

Monitor:

• Blood pressure
• Urine output
• Creatinine
• Electrolytes

Do Not Use Forced Diuresis

The historical recommendation to force urine output above 4 L/day is not appropriate as routine modern management.

Aggressive forced diuresis may cause:

• Volume overload
• Electrolyte disturbance
• Worsening renal injury

Instead:

Maintain euvolemia and adequate renal perfusion.

3. Gastrointestinal Decontamination

Do Not Induce Vomiting

Do not induce emesis.

Cantharidin is a powerful mucosal vesicant, and repeated passage through the esophagus can increase:

• Mucosal injury
• Bleeding
• Aspiration risk

Gastric Lavage

The older recommendation for routine lavage after a recent large ingestion should not be applied routinely.

Modern poisoning guidance discourages systematic gastric lavage, and cantharidin’s severe mucosal injury makes invasive GI decontamination particularly concerning.

If an extraordinarily large, immediately life-threatening ingestion has occurred, any invasive gastric decontamination decision should involve:

• Medical toxicology
• Airway protection
• Careful consideration of existing mucosal injury

Activated Charcoal

Evidence for activated charcoal specifically in human cantharidin poisoning is limited.

Single-dose charcoal may be considered after a very recent potentially severe ingestion if:

• The patient is alert with an intact airway, or intubated
• Significant vomiting/mucosal injury does not make administration unsafe
• A medical toxicologist/poison center recommends it

Routine administration is not supported by strong human outcome data.

Single-dose charcoal should not be routinely given to poisoned patients generally and should only be used when expected benefit outweighs aspiration risk.

4. GI Mucosal Injury

Supportive treatment may include:

• IV fluids
• Antiemetics
• Analgesia
• Acid suppression in significant upper-GI injury

Proton-pump inhibitors have been used in reported systemic poisoning to support healing of gastric erosions/ulceration, although evidence is based largely on case experience.

5. Hemorrhage

For clinically important blood loss:

• Type and crossmatch
• Packed RBC transfusion as required

For severe coagulopathy or DIC:

• Treat according to the clinical bleeding syndrome
• Replace blood components when indicated

6. Hypotension / Shock

Treat with:

• Isotonic crystalloid when fluid responsive
• Blood products if hemorrhage contributes

If shock persists:

Use contemporary vasopressor therapy, generally norepinephrine according to the patient’s shock physiology.

The older recommendation to preferentially use dopamine is outdated.

7. Seizures

Treat toxin-induced seizures with:

Benzodiazepines first-line

Examples:

• Lorazepam
• Midazolam
• Diazepam

For refractory seizures consider:

• Phenobarbital
• Propofol in an appropriately intubated patient

Also correct:

• Hypoglycemia
• Hypoxia
• Electrolyte disturbances

8. Acute Kidney Injury

Management includes:

• Maintain appropriate circulating volume
• Monitor urine output
• Correct electrolytes
• Avoid nephrotoxic medications

Monitor particularly for:

• Hyperkalemia
• Metabolic acidosis
• Progressive oliguria

Hemodialysis

Hemodialysis does not appear to remove cantharidin effectively.

Cantharidin:

• Is lipophilic
• Circulates extensively bound to albumin

Therefore, conventional dialysis should not be used solely as toxin-removal therapy.

However, dialysis remains appropriate for standard complications of renal failure such as:

• Refractory hyperkalemia
• Severe metabolic acidosis
• Fluid overload
• Uremic complications

Hemoperfusion / Hemofiltration

Hemoperfusion and hemofiltration have been used in severe poisoning, including recent cases of multiorgan dysfunction.

A recent review also discusses blood-purification strategies because standard hemodialysis removes the albumin-bound toxin poorly.

However:

Evidence remains limited predominantly to case reports and observational experience.

These should be considered specialist rescue strategies rather than established routine therapy.

Antidote

There is no specific antidote for cantharidin poisoning.

Current treatment is:

Supportive resuscitation + GI/renal monitoring + treatment of bleeding, seizures, shock, and renal failure

Skin Decontamination

For unintended topical exposure:

• Remove contaminated clothing
• Remove residual product promptly
• Wash thoroughly with soap and water

For the current FDA-approved preparation, inadvertent contact with healthy skin should be immediately wiped away; severe local reactions warrant earlier washing rather than waiting the usual 24 hours.

Do not intentionally neutralize cantharidin with strong acids or alkalis.

Eye Decontamination

Immediately:

• Irrigate continuously with water or saline for at least 15 minutes

Then obtain urgent medical evaluation.

Because severe ocular complications include corneal necrosis and perforation, persistent pain or vision symptoms warrant prompt ophthalmologic assessment.

Monitoring

Symptomatic systemic poisoning warrants serial:

• Vital signs
• Mental status
• CBC
• Hemoglobin
• Platelets
• Electrolytes
• BUN/creatinine
• Urinalysis
• Urine output
• Liver enzymes
• Coagulation parameters

Severe cases require:

• Continuous cardiac monitoring
• Respiratory monitoring
• Serial blood gases/lactate as indicated

Admission

Hospital admission is appropriate for:

• Any significant intentional cantharidin ingestion
• Oral/mucosal blistering
• Persistent vomiting
• Hematemesis
• Hematochezia
• Hematuria
• Proteinuria
• Acute kidney injury
• Significant electrolyte abnormalities
• Coagulopathy
• Seizures
• Dysrhythmia
• Hypotension

Because renal and systemic injury may progress after the initial GI syndrome, significant ingestions warrant ongoing inpatient observation, not simply a fixed 6-hour rule.

Severe multiorgan toxicity requires ICU management.

Disposition

The old recommendation that every asymptomatic patient can be discharged after exactly 6 hours is overly rigid.

Disposition should depend on:

• Reliability of exposure history
• Estimated concentration
• Presence of mucosal injury
• Urinalysis
• Renal function
• Hemodynamic status
• Coingestants

A clinically meaningful ingestion deserves poison-center/medical-toxicology input because renal manifestations may evolve after early gastrointestinal symptoms.

Pregnancy

The historical FDA pregnancy-category system is obsolete.

For current topical YCANTH:

• There are insufficient human pregnancy data
• Systemic exposure after appropriate topical treatment is low
• Significant fetal exposure from correctly used topical therapy is not expected according to current labeling.

This is very different from systemic poisoning.

Historically, oral cantharidin has been misused as an abortifacient and can cause severe maternal toxicity.

In poisoning:

Maternal stabilization is the priority.

Breastfeeding

For appropriately applied topical cantharidin, systemic absorption is low.

Current labeling advises avoiding application where the breastfeeding infant could:

• Ingest the product
• Contact treated skin with the eyes or mouth.

Prognosis

Mild topical exposure generally causes only local blistering and irritation.

Significant ingestion may progress rapidly to:

• GI hemorrhage
• Hematuria
• AKI
• Shock
• Multiorgan failure

Severe cases often declare major systemic involvement during the first 24–48 hours.

Renal and urinary abnormalities may persist considerably longer than the acute GI symptoms.

Mortality is uncommon with modern supportive care but can occur after concentrated systemic exposure.

Important Pitfalls

1. Calling “Spanish fly” a harmless aphrodisiac

Cantharidin does not produce a physiologic aphrodisiac response.

It causes:

Genitourinary inflammation → vascular congestion → painful priapism

and may be fatal.

2. Underestimating tiny concentrated doses

Estimated fatal doses are measured in tens of milligrams, not grams of purified cantharidin.

3. Missing delayed renal injury

The early presentation may be dominated by:

• Oral burning
• Vomiting
• GI bleeding

while:

Hematuria + oliguria + rising creatinine

develop later.

4. Forcing urine output

The old target of >4 L/day is not evidence-based and may cause harm.

Maintain appropriate euvolemia instead.

5. Using routine gastric lavage

Cantharidin causes severe mucosal injury.

Routine lavage is not modern standard management and may worsen complications.

6. Assuming hemodialysis removes cantharidin

It generally does not efficiently clear the albumin-bound toxin.

Use dialysis for renal failure complications, not routine toxin extraction.

7. Missing coagulopathy

Severe systemic poisoning may cause:

• Thrombocytopenia
• Coagulation abnormalities
• DIC

Current FDA labeling specifically warns of coagulopathy after oral exposure.

8. Missing serious eye injury

Ocular exposure can cause:

Corneal necrosis or perforation

and requires immediate irrigation and medical assessment.

9. Using the old therapeutic formulation information

Current U.S. FDA-approved cantharidin therapy is:

YCANTH 0.7% topical solution

for:

Molluscum contagiosum in patients ≥2 years

not simply a 1% wart solution.

High-Yield Toxicology Pearls

Cantharidin = vesicant GI/GU toxin

Think:

Severe GI irritation + hematemesis + hematuria + AKI after “Spanish fly”/blister beetle exposure

Key points:

• Produced by blister beetles (Meloidae)
• Historically known as Spanish fly
• Major molecular targets: PP1 and PP2A inhibition
• Potent vesicant
• Oral toxicity causes severe mucosal blistering and hemorrhage
• Genitourinary irritation causes:
• Dysuria
• Hematuria
• Proteinuria
• Priapism
• Major systemic complication: acute kidney injury
• Severe poisoning can also cause:
• Coagulopathy/DIC
• Seizures
• Shock
• Ventricular dysrhythmias
• Hepatic injury
• Estimated fatal pure-can­tharidin doses are roughly 10–60 mg, but individual variability is large
• No specific antidote
• Do not induce vomiting
• Routine gastric lavage is not recommended
• Activated charcoal has uncertain human benefit and should be individualized
• Maintain euvolemia; do not use forced diuresis
• Conventional hemodialysis does not effectively remove cantharidin
• Dialysis is used for conventional complications of renal failure
• Hemoperfusion/hemofiltration have been reported as rescue therapies, but evidence is limited
• Current FDA-approved product: YCANTH 0.7%
• FDA indication: molluscum contagiosum, age ≥2 years
• Oral YCANTH exposure can be fatal
• Eye exposure can cause corneal necrosis/perforation
• Significant ingestion requires prolonged renal, hematologic, and cardiovascular monitoring